How New Peptide Weight Loss Drugs Like Semaglutide May Finally Reduce Heart Disease Risk in Obesity | Research

The takeaway

Newer peptide-based obesity drugs like semaglutide and tirzepatide achieve far greater weight loss than older medications and may be the first to actually reduce heart attack and stroke risk in people with obesity.

<12% vs. 20-30% weight loss
Older weight loss drugs achieve less than 12% body weight reduction with no cardiovascular benefit, while bariatric surgery achieves 20-30% with clear heart protection — newer peptide drugs may bridge this gap

What the researchers found

The review compares three tiers of obesity treatment:

1. Lifestyle interventions and older pharmacotherapies: associated with less than 12% body weight reduction and no clear evidence of reduced major adverse cardiovascular events (MACE)

2. Bariatric surgery: achieves 20-30% body weight reduction and is associated with markedly lower subsequent MACE risk

3. Newer peptide-based pharmacotherapies (semaglutide, tirzepatide): show greater weight loss efficacy compared to older drugs and are being evaluated in cardiovascular outcomes trials

The review notes that obesity drug prescribing remains relatively rare, partly due to concerns about long-term safety, provider bias, and lack of clear MACE reduction evidence. However, if ongoing trials demonstrate cardiovascular benefits for the newer agents, this is likely to drive expanded use.

Why it matters

Obesity affects over 40% of U.S. adults and is a major driver of heart disease, the leading cause of death. If peptide-based weight loss drugs can demonstrate not just weight reduction but actual prevention of heart attacks and strokes, it would represent a paradigm shift in how obesity is treated — moving it from a cosmetic concern to a directly treatable cardiovascular risk factor, potentially saving hundreds of thousands of lives.

How the study worked

This is a narrative review article that surveys the evidence on weight loss therapies and their effects on major adverse cardiovascular event (MACE) risk. The authors compare lifestyle interventions, older anti-obesity pharmacotherapies, bariatric surgery, and newer peptide-based medications (semaglutide, tirzepatide) in terms of weight loss efficacy and cardiovascular outcomes.

What this study cannot tell us

As a narrative review, this does not present original data or systematic methodology. It was published before the results of key cardiovascular outcomes trials (including SELECT for semaglutide), so some of its open questions have since been answered. The review focuses primarily on U.S. obesity prevalence and treatment patterns. Cost, insurance coverage, and drug supply issues — major barriers to GLP-1 agonist adoption — are not extensively discussed.

How to read the evidence

This is a narrative review summarizing existing evidence. It does not present original data. The underlying evidence ranges from randomized controlled trials (for weight loss efficacy) to observational studies (for bariatric surgery cardiovascular outcomes). At the time of publication, the cardiovascular outcomes trials for the newer agents had not yet reported results.

When this study was published

Published in 2023, this review was written during the period of active cardiovascular outcomes trials for semaglutide and tirzepatide. Some questions raised have since been answered — notably, the SELECT trial (late 2023) confirmed semaglutide's cardiovascular benefit in obesity.

The bigger picture

This review was written at a pivotal moment — before the results of the SELECT trial (published late 2023) confirmed that semaglutide reduces cardiovascular events by 20% in people with obesity. It captures the state of anticipation in the field and accurately predicted that positive cardiovascular outcomes data would transform obesity treatment. The emergence of GLP-1 and GIP peptide agonists as potential cardiovascular drugs represents one of the most significant therapeutic developments in decades.

Questions still open

Now that semaglutide has shown cardiovascular benefit in SELECT, will tirzepatide demonstrate similar or even greater MACE reduction?
Will cardiovascular outcomes data finally overcome provider bias and insurance barriers to prescribing obesity medications?
Is the cardiovascular benefit driven primarily by weight loss, or do GLP-1 agonists have independent cardioprotective mechanisms?

Common questions

Why haven't weight loss drugs reduced heart disease risk before?

Previous obesity medications achieved relatively modest weight loss — typically less than 12% of body weight — which may not be enough to meaningfully reduce cardiovascular risk. Additionally, some older weight loss drugs were withdrawn due to cardiovascular safety concerns (like fenfluramine and sibutramine). The newer GLP-1 peptide drugs achieve substantially greater weight loss and appear to have additional cardioprotective effects beyond weight reduction alone.

How are semaglutide and tirzepatide different from older weight loss drugs?

Semaglutide and tirzepatide are peptide drugs that mimic natural gut hormones (GLP-1 and GIP) which regulate appetite, blood sugar, and metabolism. They achieve significantly more weight loss than older medications — in clinical trials, some patients lose 15-20% or more of their body weight. Older drugs worked through different mechanisms like suppressing appetite in the brain or blocking fat absorption, and were generally less effective with more side effects.

Read the original research

Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.

Expert review of endocrinology & metabolism, 18(4), 307-319

View on PubMed ↗Publisher’s paper ↗

Citation

Maki, Kevin C; Kirkpatrick, Carol F; Allison, David B; Gadde, Kishore M. (2023). Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.. Expert review of endocrinology & metabolism, 18(4), 307-319. https://doi.org/10.1080/17446651.2023.2209176